Anti-Human HLA-DQ (MHC Class II) – Purified

Home/Human MHC, Primary Monoclonal Antibodies/Anti-Human HLA-DQ (MHC Class II) – Purified

Pricing & Details

Product No.H135
HLA-DQ Monomorphic
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
HLA-DQ Monomorphic
Prod No.
Add to cart
H135-50 µg
50 µg
In stock
Min: 1
Step: 1
H135-100 µg
100 µg
In stock
Min: 1
Step: 1
H135-200 µg
200 µg
In stock
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Antibody Details

Product Details

Reactivity Species
Host Species
Product Concentration
0.5 mg/ml
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This purified antibody is stable when stored at 2-8°C. Do not freeze.
Country of Origin
Next Day Ambient
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this HLA-DQ (Clone 1a3) antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
WB The suggested concentration for this HLA-DQ (Clone 1a3) antibody for use in western blotting is 1-10 μg/ml.
Other Applications Reported In Literature ?
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.


Clone 1a3 recognizes a monomorphic epitope on human HLA-DQ1. It does not cross-react with HLA-DR or HLA-DP.
Antigen Distribution
HLA-DQ is expressed on antigen-presenting cells, including macrophages, monocytes, DCs, and B cells, and activated T cells.
HLA-DQ antibody, clone 1a3, recognizes the major histocompatibility complex (MHC) class II molecule Human Leukocyte Antigen - DQ isotype (HLA-DQ). MHC class II is constitutively expressed on human professional antigen-presenting cells (APCs), including macrophages/monocytes, dendritic cells (DCs), and B cells, and is induced on T cells upon activation2. HLA-DQ consists of two transmembrane proteins, a 35 kDa α (heavy) chain and 29 kDa β (light) chain3 encoded by the HLA-DQA1 and HLA-DQB1 genes, respectively, located in the HLA complex of chromosome 6. The N-terminal α1 and β1 domains form the antigen-binding groove, which binds 13-25 aa peptides derived from exogenous antigens4. On APCs, MHC class II plays a critical role in the adaptive immune response by presenting phagocytosed antigens to helper CD4 T cells. The T cell receptor (TCR)/CD3 complex of CD4 T cells interacts with peptide-MHC class II, which induces CD4 T cell activation leading to the coordination and regulation of other effector cells. CD4 molecules also bind to MHC class II, which helps augment TCR signaling5. It has also been demonstrated that MHC class II express on activated T cells are capable of antigen presentation6 and can transduce signals into T cells, enhancing T cell proliferation and activity7. Specific alleles of HLA-DQ are associated with autoimmune diseases, including celiac disease8 and type 1 diabetes9, and graft-versus-host disease10.

Antigen Details

NCBI Gene Bank ID
Research Area
Innate Immunity

References & Citations

1. Shookster L, et al. (1987) Hum Immunol. 20(1):59-70
2. Holling TM, Schooten E, van Den Elsen PJ. (2004) Hum Immunol. 65(4):282-90
3. Mitaksov V, Fremont DH. (2006) J Biol Chem. 281(15):10618-25
4. Wieczorek M, et al. (2017) Front Immunol. 8:292
5. Artyomov MN, et al. (2010) Proc Natl Acad Sci USA. 107(39):16916-16921
6. Barnaba V, et al (1994) Eur J Immunol. 24(1):71-5
7. Di Rosa F, et al. (1993) Hum Immunol. 38(4):251-60
8. Castaño L, et al. (2004) J Pediatr Gastroenterol Nutr. 39:80–84
9. Cucca F, et al. (1993) Hum Immunol. 37:85 –94
10. Petersdorf EW, (1996) Proc Natl Acad Sci USA. 93(26):15358-63
Elisa Sandwich Protocol
Flow Cytometry
Immunoprecipitation Protocol
General Western Blot Protocol

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy. Ok